Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma

PURPOSE: A randomized, phase III, placebo-controlled, partially blinded clinical trial (REGAL [Recentin in Glioblastoma Alone and With Lomustine]) was conducted to determine the efficacy of cediranib, an oral pan–vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, either as...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Batchelor, Tracy T., Mulholland, Paul, Neyns, Bart, Nabors, L. Burt, Campone, Mario, Wick, Antje, Mason, Warren, Mikkelsen, Tom, Phuphanich, Surasak, Ashby, Lynn S., DeGroot, John, Gattamaneni, Rao, Cher, Lawrence, Rosenthal, Mark, Payer, Franz, Jürgensmeier, Juliane M., Jain, Rakesh K., Sorensen, A. Gregory, Xu, John, Liu, Qi, van den Bent, Martin
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2013
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4021043/
https://ncbi.nlm.nih.gov/pubmed/23940216
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.47.2464
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados